Divalproex Sodium Extended-release
Product Images NDC 64725-0314

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium Extended-release (NDC 64725-0314). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Tya Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (64725 0314)

Label for Divalproex Sodium Extended-Release 250 mg tablets, packaged as 100 count bottle, prescription only. The label includes lot number and expiration date placeholders, manufacturer AbbVie Ltd., and repackager T.Y.A. Pharmaceuticals in Tallahassee, FL, with contact phone number. A barcode and instruction to see package insert for dosing are shown.*

FDA Label Image

Label Image (64725 0315)

Label for Divalproex Sodium Extended-Release 500 mg tablets in a 15 count bottle, repackaged by TYA Pharmaceuticals, Tallahassee, FL. Original manufacturer is AbbVie LTD. The label includes lot and expiration placeholders, a barcode, and instructs to see the package insert for dosing information.*

FDA Label Image

Chemical Structure Of Divalproex Sodium (Depakote Er 01)

Chemical structure diagram of the active ingredient in Divalproex Sodium Extended-Release, showing the sodium salt of valproic acid polymer with detailed molecular groups and bonds.*

FDA Label Image

Figure-1 (Img 0400)

A line graph comparing the percentage reduction in CPS rate between Valproate and placebo groups across different percentages of patients. The y-axis shows the percent reduction in CPS rate from -100% to 100%, with improvement indicated upward and worsening downward. The x-axis shows percentage of patients from 100% to 0%. The Valproate group is represented by a solid line, showing generally higher improvement compared to the placebo group, which is represented by a dashed line.*

FDA Label Image

Figure-2 (Img 0401)

A cumulative distribution plot displaying the percentage reduction in complex partial seizure (CPS) rate among patients treated with high dose and low dose valproate. The graph shows improvement and worsening on the vertical axis and percentage of patients on the horizontal axis, comparing seizure rate changes between the two dosage groups.*

FDA Label Image

Figure-3 (Img 0402)

A bar graph comparing two groups: Placebo and Divalproex sodium extended-release tablets. The vertical axis ranges from 0 to 1.2, with the Placebo bar at 0.6 and the Divalproex sodium extended-release tablets bar at 1.2, marked with a statistical significance indicator (p=0.006).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.